Marginal Zone Lymphoma - 27 Studies Found
Completed |
: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma : Marginal Zone Lymphoma : 2007-03-27 :
|
Active, not recruiting |
: Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma : Non-gastric Marginal Zone Lymphoma : 2006-09-14 : Radiation: Involved Field Radiotherapy The prescribed dose |
Not yet recruiting |
: A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) :
|
Terminated |
: Gemcitabine for Marginal Zone Lymphoma :
: 2006-06-14 : Drug: gemcitabine D1 and 8, Gemcitabine 1250mg/m2 + NS 100ml MIV over 30min, every 3 weeks |
Active, not recruiting |
: Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma :
: 2013-10-29 : Drug: ibrutinib |
Terminated |
: Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma :
: 2010-02-11 :
|
Active, not recruiting |
: Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma : Marginal Zone B-cell Lymphoma : 2016-07-26 : Drug: Bendamustine and Rituximab |
Completed |
: Endomicroscopy and Gastric MALT-lymphoma : MALT-lymphoma : 2012-01-08 :
|
Recruiting |
: Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) : Marginal Zone B-cell Lymphoma : 2015-04-05 : Drug: bendamustine plus rituximab Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 |